Open an account

Profound Medical

PROF · TORONTO

$5.56−$0.20 (−3.47%)TodayMarket closed ·
Prev close $5.76

About PROF

Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Employees
162
Headquarters
Mississauga, Ontario
Listed
Sep 24, 2014
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
profoundmedical.com

PROF key statistics

Market cap
295.18M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
340.62K
Volume
135.94K
Open price
$5.79
High today
$5.79
Low today
$5.54
52 Week high
$8.95
52 Week low
$4.80

Profound Medical (PROF) at a glance

Profound Medical (PROF) last traded at $5.56, with a market cap of 295.18M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.54 and $5.79. The current price is 0.4% above the day's low and 4.0% below its high.

Volume so far is 135.94K shares, below the average of 340.62K shares a day.

Over the past year Profound Medical has ranged from $4.80 to $8.95, and now sits 18% of the way up that range.

Profound Medical met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.26 per share against an estimate of -$0.2626.

The average analyst price target is $8.31, 49.5% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $8.31
Low
$8.23
Now
$5.56
High
$8.56

PROF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 24.8% on average.

  1. Q3 FY24: reported -$0.38 per share against an estimate of -$0.2954
  2. Q4 FY24: reported -$0.20 per share against an estimate of -$0.3501
  3. Q1 FY25: reported -$0.36 per share against an estimate of -$0.2828
  4. Q2 FY25: reported -$0.52 per share against an estimate of -$0.3712
  5. Q3 FY25: reported -$0.26 per share against an estimate of -$0.3687
  6. Q4 FY25: reported -$0.27 per share against an estimate of -$0.2693
  7. Q1 FY26: reported -$0.19 per share against an estimate of -$0.2559
  8. Q2 FY26: reported -$0.26 per share against an estimate of -$0.2626

PROF news

  • Press releaseGlobe Newswire

    Profound Medical Reports Second Quarter 2026 Financial Results

  • Press releaseGlobe Newswire

    Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

  • Press releaseGlobe Newswire

    Profound Medical Reports Strong First Quarter 2026 Financial Results

  • Press releasePRNewswire

    Why Medtech Giants Are Quietly Paying Up for AI Diagnostics

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

  • Press releaseGlobe Newswire

    Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results

  • Profound Medical's Earnings: A Preview

  • Profound Medical Announces First Prostate Cancer Patient Treated With TULSA-PRO At Mount Sinai Hospital

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.